CAI — Caris Life Sciences, Inc.

Summary of Caris Life Sciences Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Total Revenue: $293 million for Q4 2025, up 125% year-over-year.
• Molecular Profiling Services Revenue: $282 million, a 199% increase year-over-year.
• Pharma R&D Services Revenue: $10.8 million in Q4.
• Gross Margin: 75% (GAAP), up from 54% in Q4 2024.
• Net Income: Positive GAAP net income of $82 million.
• Adjusted EBITDA: $106 million for Q4; $138 million for the full year.
• Free Cash Flow: $39.7 million in Q4; $67 million for the full year.
• Cash on Hand: Exceeded $800 million, increasing by $43 million in the quarter.

2. Strategic Updates and Business Highlights:

• Caris completed nearly 200,000 individual cases in 2025, reaching a milestone of over 1 million profiled cases.
• The company is focusing on the intersection of molecular science and AI to drive innovation.
• Plans to invest significantly in the Early Detection business and Therapy Selection channel, including the upcoming launch of the Caris Detect cancer early detection test.
• New Chief Commercial Officer Bobby Hill is leading initiatives to expand the sales force and enhance customer engagement.
• The company reported strong interim results from the ACHIEVE-1 study for Caris Detect, indicating promising sensitivity and specificity metrics.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Expected to be between $1.0 billion and $1.02 billion, representing a growth of 23% to 26% compared to 2025.
• Clinical Volume Growth: Anticipated to grow approximately 20% year-over-year, with molecular profiling growth projected at 21% to 22%.
• ASP Expectations: Tissue ASP expected to reach approximately $4,000 in Q1 and $4,200 for the full year; blood ASP projected between $2,400 to $2,500.
• Operating Expenses: Expected to increase by 19% to 20%, driven by commercial expansion and R&D activities.
• CapEx: Estimated at $60 million for 2026, primarily for capacity expansion related to the early detection launch.

4. Bad News, Challenges, or Points of Concern:

• Pharma Revenue Decline: Year-over-year decrease in pharma revenue, although management expressed confidence in future growth from new partnerships.
• ASP Caution: While ASPs are expected to increase, management is taking a cautious approach to avoid overestimating potential revenue.
• Market Competition: The company faces competitive pressures, particularly in the early detection space, where other technologies are being developed.
• Regulatory and Clinical Risks: Ongoing need for clinical validation and regulatory approvals for new products, particularly the MCED test.

5. Notable Q&A Insights:

• Volume Outlook: Management expects tissue volume growth in the low teens and blood in the high 50s for 2026, with no immediate impact from new sales hires factored into guidance.
• Sales Force Expansion: Plans to increase the sales force by 20% to 25%, with expectations of productivity improvements in the latter half of the year.
• MCED Test Launch: The launch of Caris Detect is contingent on the final readout of the ACHIEVE-1 study, with interim results showing strong performance.
• Market Positioning: The company is focusing on leveraging its unique data set and technology to differentiate itself from competitors, particularly in the context of AI and precision medicine.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of Caris Life Sciences' performance and outlook.